Japan’s Fujitsu, Mizuho, PeptiDream to form joint venture to develop COVID-19 treatments

TOKYO (Reuters) – Fujitsu Ltd, Mizuho Financial Group Inc, and drugmaker PeptiDream Inc said on Thursday they are forming a joint venture to develop treatments for COVID-19.

The new company, to be called PeptiAID Inc, will research and develop peptide therapeutics for the current SARS-CoV-2 virus and potential future coronavirus outbreaks, the companies said in a release.

The joint venture also includes Takenaka Corp and Kishida Chemical Co.

(Reporting by Rocky Swift; Editing by Kim Coghill)

The post Japan’s Fujitsu, Mizuho, PeptiDream to form joint venture to develop COVID-19 treatments appeared first on Morningology.

From a college dorm room to $4.5 million

How would you like a 7-figure trader to send you his stock watchlist every Sunday? Many traders spend 5-10 hours minimum every week looking for stocks that could spike. Put in your email below and you’ll automatically get the hottest 3-5 stocks to watch every week. That’s up to 260 opportunities per year at no charge.

Legendary penny stock trader, Tim Sykes, went from school to now a featured guest on the Steve Harvey Show, Larry King LIVE and others. Yet, only in his best-selling book, An American Hedge Fund, is it revealed how he turned his bar mitzvah money into over $4.5 million in trading profits. Put in your email below and get your free copy.

Trading isn’t luck and you aren’t born with the skills. I believe it only takes hard work and discipline to trade full-time. If you’re are willing to accept that, you’re ready to apply (free) to my world-renowned Trading Challenge. Put in your email to get complete details. It doesn’t cost a penny.

Hot Topics